IntronA- behandling bør afbrydes efter 8 til 12 ugers behandling, hvis ikke mindst en partiel hæmatologisk remission eller en klinisk betydningsfuld cytoreduktion er opnået.
IntronA treatment must be discontinued after 8 to 12 weeks of treatment if at least a partial haematological remission or a clinically meaningful cytoreduction has not been achieved.